HFS
ALXN

Hantz Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Hantz Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-151
Closed -$28K – 881
2021
Q2 		$28K Sell
151
-69
-31% -$11.8K ﹤0.01% 589
2021
Q1 		$34K Sell
220
-7,314
-97% -$1.13M ﹤0.01% 532
2020
Q4 		$1.18M Sell
7,534
-121
-2% -$15.5K 0.05% 262
2020
Q3 		$876K Buy
7,655
+228
+3% +$24.6K 0.04% 284
2020
Q2 		$834K Buy
7,427
+757
+11% +$80.4K 0.05% 286
2020
Q1 		$599K Buy
+6,670
New +$655K 0.04% 284

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Hantz Financial Services's ALXN Position: Q3 2021 in Review

Hantz Financial Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 151 shares — an estimated $28K sold.

Hantz Financial Services first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $1.18M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Hantz Financial Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hantz Financial Services sold 151 Alexion Pharmaceuticals shares in Q3 2021, an estimated $28K.
  • Hantz Financial Services first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Hantz Financial Services's Alexion Pharmaceuticals position peaked at $1.18M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hantz Financial Services's 13F filing for Q3 2021, filed 1 Sep 2022.